#188

Hepatic Encephalopathy in ESLD

  • Julie Wilson Childers MD
  • Robert Arnold MD

Download PDF

Background     Hepatic encephalopathy (HE) is a neuropsychiatric syndrome with a fluctuating course associated with end stage liver disease (ESLD).  HE symptoms, which are graded from 0 to IV, range from subtle personality or sleep disturbances to confusion and coma.  Severe HE (grade III or IV) is manifested by gross disorientation, bizarre behavior, stupor, or coma (1).  Without transplantation, severe HE signifies a poor prognosis (58% 1 year and 77% 3 year mortality in one case series) (2).  In addition, 15% of patients awaiting liver transplantation die before receiving an organ (3).

Etiology     The cause of HE is uncertain, but may be related to the accumulation of neurotoxic substances normally metabolized by the liver; these include ammonia and endogenous benzodiazepine-like substances that activate GABA-receptors to cause neurotoxicity.

Evaluation     HE is a diagnosis of exclusion, and in one study 80% of cases were associated with an identifiable secondary cause such as gastrointestinal bleeding, infection (including spontaneous bacterial peritonitis), renal failure, alcohol withdrawal, excessive dietary protein, volume depletion, or drugs (particularly benzodiazepines) (4).  Because of its association with coagulopathy, brain imaging often via a CT scan without contrast, may be needed to rule out intracranial hemorrhage. Serum ammonia levels are usually elevated in HE, although the utility of following ammonia levels has not been established. 

Therapy begins with correction of the underlying causes if this is consistent with the goals of care.  Specific therapy of HE is aimed at limiting production of and increasing excretion of intestinally derived toxins, particularly ammonia.

  • Nonabsorbable disaccharides such as lactulose and lactitol are the mainstay of treatment though there is a lack of controlled evidence supporting their use (5).  These agents not only cause increased transit time through the gut and less absorption of toxins, but also promote bacterial fermentation, leading to a hostile environment for ammonia-producing bacteria. The daily dose of lactulose should be titrated to result in two to four soft stools daily. For most patients the daily dose is between 30 and 60 grams.  Side effects include gastrointestinal cramping, diarrhea, and flatulence.
  • Nonabsorbable antibiotics such as neomycin and vancomycin were the first treatments for HE.  They lower ammonia by combating urea-producing bacteria in the gut.  Neomycin likely produces more rapid improvement than lactulose but its use is limited by its nephro- and oto-toxic effects (5).  Rifaximin is a nonabsorbable derivative of rifampin which received orphan drug status from the FDA in 2005 for treatment of HE.  Rifaximin, given at 400 mg orally three times a day, is as effective as neomycin or lactitol and better tolerated than other nonabsorbable antibiotics (6).  Rifaximin costs $4.00 a pill (average wholesale price).  Because of this and its lack of clear superiority to disaccharides rifaximin is considered a second-line agent for patients who cannot tolerate or who are not responding to disaccharide therapy.
  • Other therapies have limited efficacy in treating HE and play no clear role in its management.  These include branched chain amino acids (7), the benzodiazepine antagonist flumazenil (8, 9), zinc, l-ornithine–l-aspartate and limitation of dietary protein (10).

Advance care planning    The patient’s values, goals of care, and treatment options should be discussed in the context of HE’s poor prognosis.  A health care proxy should be established in patients with cirrhosis before cognitive impairment prevents this. 

Supportive care    The patient and family must be educated to recognize HE’s symptoms, understand its fluctuating course, and avoid precipitating factors when possible. They should also be counseled about the risk of motor vehicle accidents. Patients who are confused should be reoriented and measures should be taken to prevent falls, skin breakdown, and aspiration. Intravenous fluids, nasogastric feeding, and airway protection are sometimes appropriate. Dose-adjusted acetaminophen (<2 gm/day) is the first line analgesic. Opioids can worsen HE but are sometimes necessary to adequately treat pain; their use should be closely monitored and balanced with the patient’s degree of suffering and goals of care (11).  Dying patients should receive attentive comfort care. Besides pain – dyspnea, restlessness, edema, and secretion management are common challenges in dying ESLD patients.

References

  1. Blei AT, Cordoba J.  Practice guidelines: Hepatic encephalopathy.  Am J Gastroenterology. 2001; 96(7):1968-1976.
  2. Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999; 30:890–895.
  3. Russo MW, LaPointe-Rudow D, Kinkhabwaa M, Emond J, Brown RS.  Impact of adult living donor liver transplantation on waiting time survival in candidates listed for liver transplantation. Am J Transplantation. 2004; 4(3):427–431.
  4. Fessel JM, Conn HO.  An analysis of the causes and prevention of hepatic coma. Gastroenterology. 1972; 62:191.
  5. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD003044. DOI: 10.1002/14651858.CD003044.pub2.
  6. Mas A, Rodes J, Sunyer L, et al.  Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy:  results of a randomized, double-blinded, double-dummy, controlled clinical trial.  J Hepatol. 2003; 38(1):51-8.
  7. Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD001939. DOI: 10.1002/14651858.CD001939.
  8. Barbaro G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology. 1998; 28(2):374-8.
  9. Als-Nielsen B, Gluud LL, Gluud C. Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD002798. DOI: 10.1002/14651858.CD002798.pub2.
  10. Cordoba J, Lopez-Hellin J and Planas M, et al.  Normal protein diet for episodic hepatic encephalopathy. J Hepatol. 2004; 41:38–43.
  11. Larson AM and Curtis JR.  Integrating palliative care for liver transplant candidates:  “Too well for transplant, too sick for life”.  JAMA. 2006; 295(18):2168-76.
  12. Leise, MD, Poterucha JJ, et al. Management of hepatic encephalopathy in the hospital. Mayo Clinic Proceedings. 2014; 89:241-253.

Version History:  Originally published September 2007.  Version re-copy-edited in May 2009; then again July 2015 with reference #12 added and incorporated into the text.